Enanta Pharmaceuticals, Inc., a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, announced that preclinical data for EDP-978 will be highlighted at the upcoming American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting.
EDP-978 is the Company’s KIT inhibitor currently in development for the treatment of mast cell-mediated, Type 2 immune diseases. The data will be shared across two poster presentations during the session on Allergic Skin Diseases.
Presentation Details
Abstract: Discovery of a Potent and Selective KIT inhibitor for Treatment of Mast Cell-Mediated Diseases
Session: Allergic Skin Diseases
Presenter: Tessa Cressey, Ph.D.
Abstract: EDP-978 Demonstrated Dose-Dependent Target-Engagement and a Favorable Pharmacokinetic Profile
Session: Allergic Skin Diseases
Presenter: Yang Li, Ph.D.
The findings highlight EDP-978's potential for once-daily dosing in humans, supported by its potent inhibition of KIT, a key driver in various inflammatory responses.
About Enanta Pharmaceuticals, Inc.
Enanta uses a robust, chemistry-driven approach to discover and develop small molecule drugs for viral infections and immunological diseases. The clinical programs currently focus on respiratory syncytial virus (RSV), while the immunology pipeline targets key drivers of type 2 immune response via KIT, STAT6, and MRGPRX2 inhibition.
Enanta’s discovery of Glecaprevir, part of a leading treatment for hepatitis C (HCV), continues to fund its operations through royalties from its collaboration with AbbVie.
